Polymorphisms in the 5α reductase type 2 gene and urologic measures of BPH

Rosebud O Roberts, Erik J. Bergstralh, Sara A. Farmer, Debra J. Jacobson, Michaela E. McGree, Scott J. Hebbring, Julie M Cunningham, Sarah A. Anderson, Stephen N Thibodeau, Michael M. Lieber, Steven J. Jacobsen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

BACKGROUND. The objective of the study was to examine associations between SRD5A2 polymorphisms and measures of benign prostatic hyperplasia (BPH). METHODS. Participants were 510 Caucasian men (median age 60 years), randomly selected from the Olmsted County, MN community to participate in a longitudinal study of BPH. From 1990 through 2000, biennial measurements of lower urinary tract symptom severity (assessed from the American Urological Association Symptom Index, AUASI), peak urinary flow rates (Qmax), and prostate volume were made. Genotyping of SRD5A2 V89L, A49T, and TA repeat polymorphisms were performed. RESULTS. Compared with the VV genotype, the LL genotype was associated with an enlarged prostate (Hazard ratio (HR) = 1.62, 95% confidence interval (CI) = 1.06, 2.43) but not with AUASI, Qmax, or PSA. The A49T and TA repeat polymorphisms were not associated with BPH. When the LL/VL, AT/TT, and TA(0)/TA(0) genotypes were considered high risk, the number of high risk genotypes increased with increasing prostate volume (32.3, 30.7, 34.1, and 38.7, respectively, P for trend = 0.04). CONCLUSIONS. These findings do not demonstrate consistent associations between SRD5A2 genotypes and BPH. However, they suggest that the associations of V89L polymorphisms and prostate volume should be investigated further.

Original languageEnglish (US)
Pages (from-to)380-387
Number of pages8
JournalProstate
Volume62
Issue number4
DOIs
StatePublished - Mar 1 2005

Fingerprint

Prostatic Hyperplasia
Oxidoreductases
Genotype
Prostate
Genes
Lower Urinary Tract Symptoms
Longitudinal Studies
Confidence Intervals

Keywords

  • Androgen
  • Cohort studies
  • Polymorphisms (genetics)
  • Prostate
  • Prostatic hyperplasia
  • Risk factors
  • Signs and symptoms

ASJC Scopus subject areas

  • Urology

Cite this

Roberts, R. O., Bergstralh, E. J., Farmer, S. A., Jacobson, D. J., McGree, M. E., Hebbring, S. J., ... Jacobsen, S. J. (2005). Polymorphisms in the 5α reductase type 2 gene and urologic measures of BPH. Prostate, 62(4), 380-387. https://doi.org/10.1002/pros.20142

Polymorphisms in the 5α reductase type 2 gene and urologic measures of BPH. / Roberts, Rosebud O; Bergstralh, Erik J.; Farmer, Sara A.; Jacobson, Debra J.; McGree, Michaela E.; Hebbring, Scott J.; Cunningham, Julie M; Anderson, Sarah A.; Thibodeau, Stephen N; Lieber, Michael M.; Jacobsen, Steven J.

In: Prostate, Vol. 62, No. 4, 01.03.2005, p. 380-387.

Research output: Contribution to journalArticle

Roberts, RO, Bergstralh, EJ, Farmer, SA, Jacobson, DJ, McGree, ME, Hebbring, SJ, Cunningham, JM, Anderson, SA, Thibodeau, SN, Lieber, MM & Jacobsen, SJ 2005, 'Polymorphisms in the 5α reductase type 2 gene and urologic measures of BPH', Prostate, vol. 62, no. 4, pp. 380-387. https://doi.org/10.1002/pros.20142
Roberts RO, Bergstralh EJ, Farmer SA, Jacobson DJ, McGree ME, Hebbring SJ et al. Polymorphisms in the 5α reductase type 2 gene and urologic measures of BPH. Prostate. 2005 Mar 1;62(4):380-387. https://doi.org/10.1002/pros.20142
Roberts, Rosebud O ; Bergstralh, Erik J. ; Farmer, Sara A. ; Jacobson, Debra J. ; McGree, Michaela E. ; Hebbring, Scott J. ; Cunningham, Julie M ; Anderson, Sarah A. ; Thibodeau, Stephen N ; Lieber, Michael M. ; Jacobsen, Steven J. / Polymorphisms in the 5α reductase type 2 gene and urologic measures of BPH. In: Prostate. 2005 ; Vol. 62, No. 4. pp. 380-387.
@article{7b84b4ee12e1412e9fd9f1c6fb8e891b,
title = "Polymorphisms in the 5α reductase type 2 gene and urologic measures of BPH",
abstract = "BACKGROUND. The objective of the study was to examine associations between SRD5A2 polymorphisms and measures of benign prostatic hyperplasia (BPH). METHODS. Participants were 510 Caucasian men (median age 60 years), randomly selected from the Olmsted County, MN community to participate in a longitudinal study of BPH. From 1990 through 2000, biennial measurements of lower urinary tract symptom severity (assessed from the American Urological Association Symptom Index, AUASI), peak urinary flow rates (Qmax), and prostate volume were made. Genotyping of SRD5A2 V89L, A49T, and TA repeat polymorphisms were performed. RESULTS. Compared with the VV genotype, the LL genotype was associated with an enlarged prostate (Hazard ratio (HR) = 1.62, 95{\%} confidence interval (CI) = 1.06, 2.43) but not with AUASI, Qmax, or PSA. The A49T and TA repeat polymorphisms were not associated with BPH. When the LL/VL, AT/TT, and TA(0)/TA(0) genotypes were considered high risk, the number of high risk genotypes increased with increasing prostate volume (32.3, 30.7, 34.1, and 38.7, respectively, P for trend = 0.04). CONCLUSIONS. These findings do not demonstrate consistent associations between SRD5A2 genotypes and BPH. However, they suggest that the associations of V89L polymorphisms and prostate volume should be investigated further.",
keywords = "Androgen, Cohort studies, Polymorphisms (genetics), Prostate, Prostatic hyperplasia, Risk factors, Signs and symptoms",
author = "Roberts, {Rosebud O} and Bergstralh, {Erik J.} and Farmer, {Sara A.} and Jacobson, {Debra J.} and McGree, {Michaela E.} and Hebbring, {Scott J.} and Cunningham, {Julie M} and Anderson, {Sarah A.} and Thibodeau, {Stephen N} and Lieber, {Michael M.} and Jacobsen, {Steven J.}",
year = "2005",
month = "3",
day = "1",
doi = "10.1002/pros.20142",
language = "English (US)",
volume = "62",
pages = "380--387",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Polymorphisms in the 5α reductase type 2 gene and urologic measures of BPH

AU - Roberts, Rosebud O

AU - Bergstralh, Erik J.

AU - Farmer, Sara A.

AU - Jacobson, Debra J.

AU - McGree, Michaela E.

AU - Hebbring, Scott J.

AU - Cunningham, Julie M

AU - Anderson, Sarah A.

AU - Thibodeau, Stephen N

AU - Lieber, Michael M.

AU - Jacobsen, Steven J.

PY - 2005/3/1

Y1 - 2005/3/1

N2 - BACKGROUND. The objective of the study was to examine associations between SRD5A2 polymorphisms and measures of benign prostatic hyperplasia (BPH). METHODS. Participants were 510 Caucasian men (median age 60 years), randomly selected from the Olmsted County, MN community to participate in a longitudinal study of BPH. From 1990 through 2000, biennial measurements of lower urinary tract symptom severity (assessed from the American Urological Association Symptom Index, AUASI), peak urinary flow rates (Qmax), and prostate volume were made. Genotyping of SRD5A2 V89L, A49T, and TA repeat polymorphisms were performed. RESULTS. Compared with the VV genotype, the LL genotype was associated with an enlarged prostate (Hazard ratio (HR) = 1.62, 95% confidence interval (CI) = 1.06, 2.43) but not with AUASI, Qmax, or PSA. The A49T and TA repeat polymorphisms were not associated with BPH. When the LL/VL, AT/TT, and TA(0)/TA(0) genotypes were considered high risk, the number of high risk genotypes increased with increasing prostate volume (32.3, 30.7, 34.1, and 38.7, respectively, P for trend = 0.04). CONCLUSIONS. These findings do not demonstrate consistent associations between SRD5A2 genotypes and BPH. However, they suggest that the associations of V89L polymorphisms and prostate volume should be investigated further.

AB - BACKGROUND. The objective of the study was to examine associations between SRD5A2 polymorphisms and measures of benign prostatic hyperplasia (BPH). METHODS. Participants were 510 Caucasian men (median age 60 years), randomly selected from the Olmsted County, MN community to participate in a longitudinal study of BPH. From 1990 through 2000, biennial measurements of lower urinary tract symptom severity (assessed from the American Urological Association Symptom Index, AUASI), peak urinary flow rates (Qmax), and prostate volume were made. Genotyping of SRD5A2 V89L, A49T, and TA repeat polymorphisms were performed. RESULTS. Compared with the VV genotype, the LL genotype was associated with an enlarged prostate (Hazard ratio (HR) = 1.62, 95% confidence interval (CI) = 1.06, 2.43) but not with AUASI, Qmax, or PSA. The A49T and TA repeat polymorphisms were not associated with BPH. When the LL/VL, AT/TT, and TA(0)/TA(0) genotypes were considered high risk, the number of high risk genotypes increased with increasing prostate volume (32.3, 30.7, 34.1, and 38.7, respectively, P for trend = 0.04). CONCLUSIONS. These findings do not demonstrate consistent associations between SRD5A2 genotypes and BPH. However, they suggest that the associations of V89L polymorphisms and prostate volume should be investigated further.

KW - Androgen

KW - Cohort studies

KW - Polymorphisms (genetics)

KW - Prostate

KW - Prostatic hyperplasia

KW - Risk factors

KW - Signs and symptoms

UR - http://www.scopus.com/inward/record.url?scp=13544264767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13544264767&partnerID=8YFLogxK

U2 - 10.1002/pros.20142

DO - 10.1002/pros.20142

M3 - Article

C2 - 15389785

AN - SCOPUS:13544264767

VL - 62

SP - 380

EP - 387

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -